Sickle-Cell Disease — Clinical Documentation Guide (2026)

🔍 Definition

Sickle-cell disease (SCD) is a group of inherited hemoglobin disorders caused by a point mutation in the beta-globin gene (HBB) that produces abnormal hemoglobin S (HbS). When HbS is present in sufficient quantity, red blood cells polymerize under low-oxygen conditions, deforming into rigid, sickle-shaped cells that obstruct microvascular blood flow, causing vaso-occlusion, hemolytic anemia, and multi-organ damage. Per the National Heart, Lung, and Blood Institute (NHLBI), sickle-cell disease affects approximately 100,000 Americans — predominantly those of African, Mediterranean, Middle Eastern, and South Asian descent — and represents the most common serious inherited blood disorder in the United States.

The most severe and common genotype is homozygous HbSS (sickle-cell anemia, historically called “Hb-SS disease”). Other clinically significant genotypes include HbSC disease, HbS-β⁰ thalassemia (functionally as severe as HbSS), and HbS-β⁺ thalassemia (milder course). Each genotype carries distinct ICD-10-CM coding implications under the FY2026 D57.xx category.

For ICD-10-CM purposes, SCD maps to CMS ICD-10-CM category D57 (Sickle-cell disorders), with subcategories capturing genotype, crisis type, and specific acute or chronic complications. Precise code selection requires documentation of the genotype (HbSS, HbSC, HbS-β⁰, HbS-β⁺, other), current crisis status, and the specific complication driving the encounter.

🗂️ Alternative Terminology

Multiple clinical and lay terms are used interchangeably in documentation. Coders must map these to the correct D57 subcategory.

🩺 Signs & Symptoms

Clinical presentation varies by genotype, age, and crisis type. Documentation must be specific enough to support the most granular ICD-10-CM subcategory available.

• Vaso-occlusive crisis (VOC/pain crisis): Severe, acute pain in bones, chest, abdomen, or joints; fever; tachycardia. Most common reason for ED visits and hospitalizations. Per NHLBI guidelines, VOC accounts for over 90% of SCD hospitalizations.
• Acute chest syndrome (ACS): New pulmonary infiltrate on chest X-ray with fever ≥38.5°C, respiratory symptoms (chest pain, cough, hypoxia, tachypnea). Second most common cause of hospitalization; leading cause of death in SCD.
• Splenic sequestration: Rapid spleen enlargement with acute fall in hemoglobin (>2 g/dL), thrombocytopenia, left upper quadrant pain; hypovolemic shock possible. Primarily in children before autosplenectomy.
• Cerebral vascular involvement: Acute stroke (ischemic or hemorrhagic), transient ischemic attack, or silent cerebral infarct detected on MRI. Children with HbSS have up to 11% lifetime stroke risk without prophylaxis.
• Dactylitis: Symmetric swelling and pain in hands/feet; often the presenting crisis in infants aged 6–24 months.
• Chronic hemolytic anemia: Baseline hemoglobin 6–9 g/dL (HbSS); jaundice; cholelithiasis (pigment stones); elevated LDH, indirect bilirubin.
• Chronic organ damage: Nephropathy (hematuria, proteinuria, CKD), avascular necrosis (femoral/humeral head), pulmonary hypertension, leg ulcers, retinopathy, priapism (males), cardiomegaly.
• Aplastic crisis: Sudden drop in hemoglobin due to Parvovirus B19 infection suppressing erythropoiesis.

🧭 Differential Diagnosis

Several conditions share features with SCD or its acute complications. Clinical context and laboratory findings differentiate them.

📋 Clinical Indicators for Coders/CDI

The following clinical findings support documentation and coding specificity for sickle-cell disease. CDI specialists should review these indicators against the medical record before finalizing code assignment per AHIMA and ACDIS standards.

🦴 Anatomy & Pathophysiology

Sickle-cell disease results from a single nucleotide substitution (glutamic acid → valine) at codon 6 of the beta-globin gene on chromosome 11. This produces hemoglobin S (HbS), which polymerizes under hypoxic conditions, creating long rigid chains that deform erythrocytes into the characteristic crescent shape.

Vaso-occlusion cascade: Sickled cells are rigid, dense, and adhesive. They adhere to vascular endothelium via P-selectin/E-selectin pathways (target of crizanlizumab) and interact with activated leukocytes and platelets, creating a “tangled” obstruction in postcapillary venules. The resulting ischemia triggers inflammatory cytokine release, oxidative stress, and endothelial injury, amplifying the cycle of sickling and reperfusion injury.

Hemolysis: Sickled RBCs are fragile, with a lifespan of 10–20 days (vs. 120 days for normal RBCs). Intravascular hemolysis releases free hemoglobin and arginase, depleting nitric oxide (NO) — a potent vasodilator. Chronic NO depletion contributes to pulmonary hypertension, priapism, leg ulcers, and stroke risk. This explains why fetal hemoglobin (HbF) induction — the mechanism of both hydroxyurea and Casgevy gene therapy — reduces complications: HbF does not participate in HbS polymerization.

Organ damage progression:

• Spleen: Repetitive infarction leads to autosplenectomy in HbSS by age 5, causing functional asplenia and dramatically increased susceptibility to encapsulated organisms (Streptococcus pneumoniae, Haemophilus influenzae, Salmonella).
• Kidneys: Medullary hypoxia and repeated sickling cause sickle cell nephropathy — early hematuria/proteinuria, loss of concentrating ability, progressing to CKD and ESRD in 4–18% of patients.
• Brain: Cerebral vasculopathy (Moyamoya-pattern) from chronic sickle injury to large vessels; transcranial Doppler (TCD) screening identifies children at highest stroke risk. Per NHLBI, chronic transfusion therapy reduces stroke risk by ~90% in high-TCD children.
• Bone: Intramedullary sickling causes avascular necrosis (most commonly femoral head and humeral head). Bone marrow expansion due to chronic hemolysis causes characteristic “hair-on-end” skull radiograph findings.
• Lungs: ACS is both a cause and consequence of fat embolism, infection, and in-situ pulmonary sickling. Recurrent ACS leads to pulmonary fibrosis and pulmonary hypertension (I27.2x).

💊 Medication Impact / Treatment

Medication documentation directly affects ICD-10-CM code assignment, CPT coding, HCPCS billing, and risk adjustment. The following agents are relevant to FY2026 encounters.

Preview ends here. The full guide continues with FY2026 ICD-10-CM code sets, CPT surgical coding, MS-DRG mapping, reimbursement guidance, CDI query templates, and an audit checklist — all available to CCO Members.

← Back to All Clinical Documentation Guides

📘 ICD-10-CM Guidelines (FY2026)

The following guidelines govern assignment of D57.xx codes per the FY2026 ICD-10-CM Official Guidelines for Coding and Reporting (effective October 1, 2025):

General Sequencing Rules

• Principal diagnosis: For inpatient admissions, the condition established after study that is chiefly responsible for the admission. In SCD crises, the specific crisis code (e.g., D57.01 ACS, D57.02 splenic sequestration) is the principal diagnosis — NOT the underlying D57 category code alone.
• Code also: The D57 category includes a tabular instruction to “Use additional code for any associated fever (R50.81).” Code fever when documented as present during a sickle-cell crisis, but only when clinically documented.
• Acute chest syndrome: ACS in SCD is coded to the specific D57.x1 subcategory (e.g., D57.01 for HbSS). Do NOT separately code pneumonia or acute respiratory failure unless the provider explicitly documents these as separate, co-existing diagnoses distinct from the ACS.
• Cerebral vascular involvement (D57.03 and parallel codes): Use D57.03 (or genotype-equivalent) when sickle-cell related cerebral ischemia or cerebral vascular disease is documented. Per the AHA Coding Clinic (Issue 4, 2020), the cerebral vascular involvement codes were created to capture stroke and silent cerebral infarcts as direct complications of SCD. Code also any documented stroke (I63.xx) sequentially after the D57 code when the manifestation requires separate coding for inpatient care.
• Complications: Chronic complications (CKD, AVN, pulmonary hypertension, priapism) are coded as additional diagnoses when present, meet the UHDDS definition (evaluated, treated, or increases LOS), and are documented by the provider.

FY2026 Code Updates — D57 Category

The D57 category has undergone significant expansion over FY2020–FY2026 to capture crisis-type and complication specificity. Key FY2026-effective codes (October 1, 2025) include the complete subclassification system below. The cerebral vascular involvement subcodes (D57.03, D57.213, D57.413, D57.813) and “other specified complication” subcodes (D57.09, D57.218, D57.418, D57.818) reached full tabular inclusion after AHA Coding Clinic guidance in 2020. The dactylitis subcodes (D57.04, D57.214, D57.414, D57.434, D57.454, D57.814) were added effective October 1, 2023 (FY2024) and remain valid for FY2026. The sickle-thalassemia beta-zero and beta-plus distinctions (D57.42x, D57.43x, D57.44x, D57.45x) also provide clinically meaningful genotype differentiation. Verify current code activation with the CMS FY2026 ICD-10-CM Tabular List before submission.

Sequencing — Crisis vs. Complication

When a patient with HbSS presents with both an acute pain crisis AND avascular necrosis of the femoral head:

1. Sequence D57.00 (or more specific crisis code) as principal diagnosis if the acute crisis prompted the admission.
2. Add M87.052 (Idiopathic aseptic necrosis of bone, left femur — or site-specific) as an additional diagnosis if evaluated or treated during the stay.
3. Add N18.xx (CKD stage) if present and meeting UHDDS definition.

Long-Term Transfusion / Medication Status

Per ICD-10-CM Guidelines Section I.C.21.c.3, Z79.899 (Long-term [current] use of other medication) should be assigned as an additional code when the patient is on hydroxyurea as an ongoing medication. Z79.899 also applies to crizanlizumab or L-glutamine if on long-term use. For regular transfusion programs (stroke prevention), there is no specific Z code for “regular transfusion program” — instead, document the clinical rationale, and assign Z51.89 (encounter for other specified aftercare) when the admission is solely for the transfusion.

🔢 ICD-10-CM Code Set (FY2026)

Associated / Complication Codes

🔎 Indexing

The ICD-10-CM Alphabetic Index paths for sickle-cell disorders are as follows (reference the FY2026 Alphabetic Index for confirmation):

• Disease, sickle-cell → D57.1 (without crisis, default) — then see subterms for genotype and crisis type
• Disease, sickle-cell, Hb-SS → D57.1 without crisis; with crisis → D57.00; crisis unspecified
• Disease, sickle-cell, Hb-C → D57.20 (without crisis); with crisis D57.219; with ACS D57.211
• Anemia, sickle-cell → see Disease, sickle-cell
• Trait, hemoglobin S → D57.3
• Crisis, sickle-cell → see Disease, sickle-cell, with crisis
• Sequestration, spleen (sickle-cell) → D57.02 (HbSS) or genotype-specific
• Syndrome, acute chest, sickle-cell → D57.01 (or genotype-equivalent)
• Dactylitis, sickle-cell → D57.04 (HbSS) or genotype-equivalent

🏥 CPT (2026)

The following CPT codes are relevant to sickle-cell disease management, inpatient and outpatient. All CPT codes and descriptors are per the AMA CPT 2026 codebook.

MS-DRG Mapping

Sickle-cell disease inpatient encounters map primarily under MDC 16 (Diseases and Disorders of the Blood and Blood-Forming Organs) per the CMS MS-DRG v43 grouper:

• MS-DRG 811: Red blood cell disorders with MCC
• MS-DRG 812: Red blood cell disorders with CC
• MS-DRG 813: Red blood cell disorders without CC/MCC

The presence of ACS, CKD Stage 4/5, respiratory failure, or other qualifying MCC/CC conditions significantly impacts DRG assignment and reimbursement. Accurate documentation of ALL active co-morbidities and complications (cerebral vascular involvement, AVN, pulmonary hypertension) is essential for appropriate MS-DRG capture.

🧾 HCPCS (2026)

📚 AHA Coding Clinic (Recent Guidance)

The following AHA Coding Clinic guidance is directly applicable to sickle-cell disease coding. Per AHA Central Office, Coding Clinic represents the official source of ICD-10-CM/PCS coding guidance.

💰 HCC / Risk Adjustment (v28)

Under the CMS-HCC Model v28 — fully operative as of payment year 2026 (100% v28) — sickle-cell disorders carry meaningful RAF weight reflecting their high healthcare utilization and severity.

✍️ CDI Query Templates

All query templates below are non-leading, compliant with ACDIS and AHIMA query standards. Queries offer multiple choice options including “clinically undetermined” to avoid leading the provider.

🧑‍⚕️ Treatments (Clinical)

Clinical treatment of sickle-cell disease follows NHLBI evidence-based management guidelines and involves acute crisis management, disease-modifying therapy, and prevention of chronic complications.

Acute Crisis Management

• Pain/VOC: Aggressive IV/SC opioid analgesia (morphine, hydromorphone) with scheduled dosing; IV fluids; supplemental oxygen if hypoxic; NSAIDS as adjuncts. Avoid excessive fluid administration increasing ACS risk. Per NHLBI, patient-controlled analgesia (PCA) reduces time to effective pain control.
• Acute Chest Syndrome: Incentive spirometry, broad-spectrum antibiotics (macrolide + cephalosporin to cover Chlamydia, Mycoplasma, and typical organisms), simple or exchange transfusion (raise HbS fraction <30%), supplemental O₂. Mechanical ventilation if respiratory failure develops.
• Splenic Sequestration: Emergent fluid resuscitation, transfusion to restore hemoglobin (cautiously — risk of hyperviscosity with rapid splenic release). Splenectomy for recurrent sequestration.
• Stroke (Acute): Exchange transfusion to rapidly lower HbS fraction <30%; thrombolytics generally contraindicated given hemolytic background.

Disease-Modifying Therapy

• Hydroxyurea: FDA-approved 1998; increases HbF, reduces WBC and sickling tendency. Recommended for all patients with HbSS or HbS-β⁰ thalassemia, starting from age 9 months per NHLBI 2014 guidelines. Monitoring: CBC every 2–3 months; adjust dose to maximum tolerated dose (MTD).
• Crizanlizumab (Adakveo): IV infusion every 4 weeks (after two loading doses); blocks P-selectin. SUSTAIN trial showed 45% reduction in annual VOC rate vs. placebo in SCD patients ages ≥16. HCPCS J0791.
• L-glutamine (Endari): Oral amino acid powder BID; reduces oxidative stress. Modest clinical benefit in SUSTAIN trial; FDA-approved 2017. Ages ≥5 years. Useful add-on for patients with persistent VOC on hydroxyurea.
• Gene therapies (Casgevy / Lyfgenia): One-time potentially curative approaches requiring hematopoietic stem cell collection, busulfan conditioning, and infusion at authorized treatment centers. Casgevy FDA-approved December 8, 2023. Not widely accessible due to cost (~$2.2 million per treatment) and infrastructure requirements.

Preventive / Chronic Complication Management

• Stroke prevention: Annual TCD screening in children ages 2–16; chronic transfusion if TCD velocity >200 cm/s (reduces stroke risk by ~90%).
• Pneumococcal prophylaxis: Penicillin V prophylaxis from birth to at least age 5; pneumococcal, meningococcal, and Hib vaccines essential given functional asplenia.
• Folate supplementation: Folic acid 1 mg/day to support chronic hemolytic anemia and erythropoiesis.
• Iron chelation: Deferasirox (Exjade/Jadenu) or deferoxamine for transfusional iron overload; serum ferritin and liver iron concentration monitoring.
• Hematopoietic stem cell transplant (HSCT): Curative in select patients (matched sibling donor); best outcomes in young patients without severe organ damage.

🎓 Patient Education / Summary

For patients and families, sickle-cell disease is a lifelong inherited blood condition where red blood cells can change shape under certain conditions, blocking small blood vessels and causing pain, organ damage, and other complications. The following points support patient communication and may inform documentation that coders and CDI specialists can reference.

• Understanding genotype: The type of sickle-cell disease (HbSS, HbSC, HbS-beta thal) affects severity and treatment options. Patients should know and document their genotype — confirmed by hemoglobin electrophoresis (blood test).
• Crisis triggers: Dehydration, cold temperatures, infections, stress, high altitude, and overexertion can trigger a pain crisis (vaso-occlusive episode). Staying hydrated, warmly dressed, and current on vaccinations (especially pneumococcal) reduces crisis frequency.
• Medication adherence: Hydroxyurea must be taken daily as prescribed — skipping doses reduces its effectiveness. Regular blood counts are needed to monitor for bone marrow suppression. Patients on crizanlizumab require IV infusions every 4 weeks.
• When to seek emergency care: Fever >38.5°C, difficulty breathing, sudden severe headache or one-sided weakness (stroke symptoms), rapid spleen enlargement (left-side pain/fullness), prolonged painful erection (priapism >4 hours), or acute vision changes require immediate emergency evaluation. Reference CDC sickle cell resources.
• Specialist care: Regular follow-up with a hematologist experienced in sickle-cell disease; annual kidney function tests, eye exams, echocardiogram (pulmonary hypertension screening), and transcranial Doppler (children) are recommended per NHLBI guidelines.
• Genetic counseling: Carrier screening (sickle-cell trait, D57.3) is important for family planning. Two parents who each carry the trait have a 25% chance of having a child with sickle-cell disease. The Sickle Cell Disease Association of America (SCDAA) provides patient support resources.
• Gene therapy option: Casgevy (exa-cel) and Lyfgenia represent potential one-time treatments at authorized centers for eligible patients (ages ≥12 with recurrent VOCs). Discuss eligibility with a hematologist.

About this Guide

This Clinical Documentation Guide is published by CCO Academy and is intended for credentialed coding, CDI, and clinical documentation professionals. Content is updated for FY2026 ICD-10-CM (effective October 1, 2025). All code assignments should be verified against the official ICD-10-CM Tabular List, AHA Coding Clinic, and applicable payer-specific policies. This guide does not constitute legal, medical, or compliance advice.

Last reviewed: April 2026 · Next scheduled review: October 2026 (FY2027 update)